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Discussion {#onco12820-sec-0006}
==========

Lung cancer is the most common malignancy, accounting for 12.9% of all new cancer diagnoses, and the most common cause of cancer deaths \[[1](#onco12820-bib-0001){ref-type="ref"}\]. Median age at diagnosis of lung cancer has been reported to be 63--70 years \[[2](#onco12820-bib-0002){ref-type="ref"}\], \[[3](#onco12820-bib-0003){ref-type="ref"}\], \[[4](#onco12820-bib-0004){ref-type="ref"}\], \[[5](#onco12820-bib-0005){ref-type="ref"}\], \[[6](#onco12820-bib-0006){ref-type="ref"}\], and NSCLC represents 85% of lung cancer in elderly patients \[[7](#onco12820-bib-0007){ref-type="ref"}\], \[[8](#onco12820-bib-0008){ref-type="ref"}\], \[[9](#onco12820-bib-0009){ref-type="ref"}\]. Treatment of elderly patients requires particular care for several reasons. Elderly patients typically have more comorbidities than younger patients, requiring concurrent management. Physiological functions decline with aging, such that some patients tolerate therapy more poorly. Furthermore, concurrent noncancer therapies may interfere with the metabolism of chemotherapeutic drugs. Afatinib, a second‐generation EGFR TKI, showed a proliferation‐inhibitory effect on a lung cancer cell strain that had T790M mutation \[[10](#onco12820-bib-0010){ref-type="ref"}\]; however, as for safety in the elderly, the medical evidence is not yet clear, unlike that for the first‐generation EGFR TKI.

Osimertinib, a third‐generation EGFR TKI that irreversibly inhibits EGFR, demonstrates inhibitory activity against tumor cells harboring sensitizing EGFR mutations and also selective inhibitory activity against tumor cells harboring the TKI‐resistant mutation T790M \[[11](#onco12820-bib-0011){ref-type="ref"}\], and is a first‐line treatment for EGFR mutation‐positive NSCLC \[[12](#onco12820-bib-0012){ref-type="ref"}\]. The grade ≥3 adverse events reported in patients receiving osimertinib as a first‐line treatment in the AURA study \[[12](#onco12820-bib-0012){ref-type="ref"}\], AURA extension study \[[13](#onco12820-bib-0013){ref-type="ref"}\], and AURA2 study \[[14](#onco12820-bib-0014){ref-type="ref"}\] were rash (2%, 1%, and 1%, respectively) and diarrhea (3%, 1%, and 1%, respectively). These results suggest the possibility of relatively safe use of osimertinib with few serious adverse events for the elderly in comparison with conventional EGFR TKIs.

![Waterfall plot of maximum changes in tumor size (diameter) from baseline in individual patients during the treatment.](onco12820-fig-0001){#onco12820-fig-0001}

In the present study, which included 36 patients with EGFR T790M mutation‐positive NSCLC with ineffective prior EGFR TKI treatment or with recurrence, the ORR was 58.3% (95% CI, 42.2%--72.9%), the DOR was 27.9 weeks (95% CI, 21.1--82.0), and the DCR was 97.2% with osimertinib 80 mg administration. Because the lower limit of the estimated CI exceeded a threshold of 35%, a statistically significant improvement in the ORR was demonstrated. The ORR in the present study performed in elderly patients was comparable to that in the nonelderly population \[[13](#onco12820-bib-0013){ref-type="ref"}\], \[[14](#onco12820-bib-0014){ref-type="ref"}\], \[[15](#onco12820-bib-0015){ref-type="ref"}\]. In addition, a waterfall plot revealed that 33 (91.6%) subjects exhibited tumor shrinkage during treatment, including 12 of 14 subjects who had SD.

There were no fatal events and no adverse events that required dose reduction or discontinuation of the study drug. The results of previous findings and the present study suggest that osimertinib may be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation.

Trial Information {#onco12820-sec-0007}
=================

DiseaseLung cancer -- NSCLCStage of Disease/TreatmentMetastatic/advancedPrior TherapyMore than two prior regimensType of Study ‐ 1Phase IIType of Study ‐ 2Single armPrimary EndpointOverall response rateSecondary EndpointToxicityAdditional Details of Endpoints or Study Design **Study design:** This study was a single‐arm, open‐label trial. The rationale and design of the present study have been published elsewhere \[[16](#onco12820-bib-0016){ref-type="ref"}\]. **Inclusion criteria:** The inclusion criteria were (a) histologically or cytologically confirmed stage IIIB--IV NSCLC and postoperative recurrence; (b) recurrence after a response better than SD or not effective (less than SD) observed in best overall response according to RECIST after treatment with EGFR TKI (e.g., erlotinib, gefitinib, afatinib) for NSCLC or (c) NSCLC harboring activating EGFR mutations with or without T790M mutation; (d) able to accept treatment with oral medicine; (e) at least one measurable lesion according to RECIST criteria; (f) Eastern Cooperative Oncology Group (ECOG) performance status 0--1; (g) in principle, capable of participating in this study for at least A 2‐week hospital stay or corresponding management; (h) ≥75 years of age (at the time of enrollment); (i) bone marrow, hepatic, and renal functions confirmed normal within 14 days prior to enrollment according to clinical test standards (white blood cell count ≥3,000/mm^3^ to ≤12,000/mm^3^, neutrophil count ≥1,500/mm^3^, platelet count ≥100,000/mm^3^, hemoglobin ≥9.0 g/dL, aspartate aminotransferase, alanine aminotransferase ≤100 IU/L, total bilirubin ≤1.5 mg/dL, creatinine ≤2.0 mg/dL, or SpO~2~ \[room air\] ≥90%); (j) life expectancy of at least 3 months; (k) prior treatment having passed the planned starting point of administration (for chemotherapy, ≥4 weeks have passed since the final treatment of prior chemotherapy; for EGFR TKI, the next day after the last administration; for radiation therapy in the case of radiation to the chest, ≥12 weeks have passed since the day of final radiation treatment; for radiation therapy in the case of radiation to other than the chest, ≥2 weeks have passed since the day of final radiation treatment; for an operation or treatment, including chest drainage, ≥4 weeks have passed since the day of final operation or treatment); and (l) having provided written informed consent to participate in the study. **Exclusion criteria:** The exclusion criteria were (a) treatment history of osimertinib or other third‐generation EGFR TKI; (b) pulmonary disorders such as idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, and drug‐induced pneumonia; (c) infectious disorders requiring intravenous injection of antibacterial drugs or antimycotics; (d) inability to swallow oral medications; (e) currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of cytochrome P450 3A4 (CYP3A4; at least 1 week prior) or potent inducers of CYP3A4 (at least 3 weeks prior; all patients avoided concomitant use of any medications, herbal supplements, and/or ingestion of foods with known inducer or inhibitory effects on CYP3A4); (f) currently receiving checkpoint inhibitor; (g) patients with certain cardiac criteria (mean resting corrected QT interval \[using Fridericia formula\] \>470 ms; any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram \[e.g., complete left‐bundle branch block, third‐degree heart block, second‐degree heart block\]; any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first‐degree relatives, or any concomitant medication known to prolong the QT interval), (h) those who are pregnant, nursing, or possibly pregnant; (i) symptomatic brain metastases; (j) active double cancer; (k) patients with uncontrollable diabetes mellitus; (l) complications of clinical concern (such as uncontrollable cardiac disease, severe cardiac arrhythmia requiring medical treatment, sustained serious diarrhea); (m) regarded as unsuitable for this study by the investigators. **Ethics:** The study was conducted in accordance with ethical principles originating in the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013), Ethical Guidelines for Medical and Health Research Involving Human Subjects (December 22, 2014), and Ethical Guidelines for Human Genome/Gene Analysis Research (March 29, 2001). The study received ethical approval from the Ethics Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan (number ERB‐C‐630‐3, the last edition version 3, December 21, 2016). The trial was subject to the supervision and management of the Ethics Committee. All patients provided written informed consent. **Endpoints:** The primary endpoint was ORR defined as the proportion of subjects whose best overall response was either CR or PR. Secondary endpoints were DCR defined as the percentage of patients who have achieved CR, PR, or SD, and safety. Depth of response (DpR), defined as maximum percent change in tumor reduction from baseline, was calculated for each subject and plotted with response status (waterfall plot). Grade and frequency of each adverse event and laboratory abnormality were recorded. **Statistical analysis:** For the primary endpoint (ORR), response rate and its two‐sided 95% CI were calculated using Wilson\'s method. When the lower limit of the estimated CI exceeded a threshold of 35%, statistical significance was decided. Disease control rate (DCR) and its 2‐sided 95% CI were calculated (Wilson\'s method). Investigator\'s AnalysisActive and should be pursued further

Drug Information {#onco12820-sec-0008}
================

Drug 1  **Generic/Working Name**Osimertinib **Company Name**AstraZeneca **Drug Type**Small molecule **Drug Class**EGFR **Dose**Milligrams (mg) per flat dose **Route**Oral (p.o.) **Schedule of Administration**Osimertinib 80 mg OD tablet was orally administered until progressive disease occurred or a criterion for discontinuation was met.

Patient Characteristics {#onco12820-sec-0009}
=======================

**Number of Patients, Male**13**Number of Patients, Female**23**Stage**IIIB: 1, IV: 25, Postoperative recurrence: 10**Age**Median (range): 79.9 years**Number of Prior Systemic Therapies**Median (range): Not collected**Performance Status: ECOG**0 --- 81 --- 282 --- 03 --- 0Unknown --- 0**Other** A total of 36 patients were enrolled at 21 study centers. All 36 patients were included in the efficacy and safety analyses. Among the 36 subjects, 63.9% were female, with mean age of 79.9 years; 97.2% of the subjects had adenocarcinoma, 69.4% were at stage IV, and 27.8% had postoperative recurrent NSCLC. All patients were harboring EGFR T790M mutation: 61.1% had exon 19 deletion, and 30.6% had L858R mutation. **Cancer Types or Histologic Subtypes**Adenocarcinoma, 35; Combined SCLC with adenocarcinoma, 1

Primary Assessment Method {#onco12820-sec-0010}
=========================

TitleORRNumber of Patients Enrolled36Number of Patients Evaluable for Toxicity36Number of Patients Evaluated for Efficacy36Evaluation MethodRECIST 1.1Response Assessment CR*n* = 1Response Assessment PR*n* = 20Response Assessment SD*n* = 14Response Assessment PD*n* = 1Response Assessment OTHER*n* = 0Outcome NotesThe ORR was 58.3% (95% CI, 42.2%--72.9%), demonstrating statistically significant efficacy of osimertinib (*p* = 0.0017). The median of the DOR was 27.9 weeks (95% CI, 21.1--82.0). CR and PR were 2.8% and 55.6%, respectively. DCR was 97.2%. The waterfall plot shows that 33 (91.6%) subjects exhibited tumor shrinkage during treatment, including 12 of 14 subjects who had SD. DpR ≥50% was achieved in 11 (30.5%) subjects and ≥30% in 26 (72.2%) subjects.

Adverse Events {#onco12820-sec-1010}
==============

imageJohn Wiley & Sons, Ltd.[^1]

 {#onco12820-sec-2011}

Adverse Events LegendAdverse events reported in 10% or more cases were fatigue (38.9%), decreased appetite (38.9%), diarrhea (36.1%), rash (33.3%), paronychia (33.3%), pruritus (22.2%), oral mucositis (11.1%), nausea (11.1%), and fever (11.1%).

Assessment, Analysis, and Discussion {#onco12820-sec-0011}
====================================

CompletionStudy completedInvestigator\'s AssessmentActive and should be pursued further

 {#onco12820-sec-1011}

To the authors' knowledge, this is the first prospective study to examine the efficacy and safety of osimertinib in elderly patients with epidermal growth factor receptor (EGFR) mutation T790M‐positive non‐small‐cell lung cancer (NSCLC) with disease progression on prior treatment. In the AURA phase II extension study performed in patients with EGFR mutation T790M‐positive advanced NSCLC and progression after EGFR tyrosine kinase inhibitor (TKI) treatment \[[13](#onco12820-bib-0013){ref-type="ref"}\], the objective response rate (ORR) was 62% (95% confidence interval \[CI\], 54%--68%), and in the AURA 2 phase II and AURA 3 phase III studies in patients after NSCLC progression on frontline EGFR TKI, ORR was 51%--71% \[[14](#onco12820-bib-0014){ref-type="ref"}\], \[[15](#onco12820-bib-0015){ref-type="ref"}\]. In comparison, the ORR of docetaxel, which is the standard treatment for elderly patients in Japanese guidelines, has been reported to be 22.7% in a controlled study with vinorelbine and 41.2% in a study of combined carboplatin and pemetrexed in elderly Japanese patients \[[17](#onco12820-bib-0017){ref-type="ref"}\], \[[18](#onco12820-bib-0018){ref-type="ref"}\]. Based on these findings, the expected response rate and threshold response rate are estimated to be 60% and 35%, respectively. Assuming a two‐sided significance level of 5% and a power of 80%, 31 subjects were required. Considering dropouts, 35 subjects were to be enrolled in the study. In the present study, ORR was 58.3% (95% CI, 42.2%--72.9%), duration of response was 27.9 weeks (95% CI, 21.1--82.0), and the disease control rate was 97.2% with osimertinib 80 mg administration in 36 elderly subjects with EGFR T790M‐positive NSCLC. Because the lower limit of the estimated CI exceeded a threshold of 35%, statistically significant improvement in the ORR was demonstrated. The ORR in the present study performed in elderly patients was comparable to those in the nonelderly population. In addition, waterfall plot revealed that 33 (91.6%) subjects exhibited tumor shrinkage during treatment, including 12 of 14 subjects who had stable disease.

The most common side effects observed in the AURA phases I--II and AURA 2 studies were gastrointestinal symptoms (diarrhea, 47%; nausea, 22%; and decreased appetite, 21%), followed by dermatologic side effects (rash, 40%; dry skin; and pruritus), and a fatal event was reported as being possibly drug‐related. Hyperglycemia and QT prolongation were seen in 2% and 4%, respectively, which required no dose reduction \[[19](#onco12820-bib-0019){ref-type="ref"}\]. In the present study, as for the gastrointestinal symptoms, decreased appetite was observed in more patients compared with those in the AURA studies (38.9% vs. 21%); however, diarrhea (36.1% vs. 47%) and nausea (11.1% vs. 22%) were less frequent. Among these, grade ≥3 events were decreased appetite (11.1%) and diarrhea (2.8%). The most frequent dermatological symptom, rash, was less frequent in the present study versus that of the AURA studies (33.3% vs. 40%), followed by paronychia in 33.3%, but neither of these was grade ≥3. There were no fatal events and no adverse events that required dose reduction or discontinuation of the study drug.

A recently conducted retrospective study compared the frequency of adverse events associated with osimertinib between elderly (aged ≥75 years) and nonelderly (aged \<75 years) patients with advanced NSCLC with EGFR T790M mutation \[[20](#onco12820-bib-0020){ref-type="ref"}\]. Comparison was also performed between the initial EGFR TKI treatment before osimertinib administration in the same patient cohort. The results showed that the only grade ≥2 event that was significantly more frequent in the elderly group compared with the nonelderly group was paronychia (16.6% vs. 1.6%; *p* = .04), and the maximum grade of EGFR TKI‐related adverse events associated with osimertinib in the elderly group was significantly lower than that of the initial EGFR TKI treatment (*p* = .03).

To obtain conclusive results, further studies in a larger elderly population is warranted.

Taking together the results of previous findings and the present study, osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation.

Figure {#onco12820-sec-3013}
======

![Kaplan‐Meier curve shows the duration of response, defined as the time from the achievement of a response to progression, among 26 responders. The median of the duration of response was 27.9 weeks (95% confidence interval, 21.1--82.0 weeks).](onco12820-fig-0002){#onco12820-fig-0002}
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